IOVA · Insider Trading
Iovance Biotherapeutics, Inc. Common Stock
Every open-market purchase and sale reported by IOVA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Noah Berkowitz | Chief Medical Officer | A | +450,000 deriv. | — |
| 2026-09-10 | Igor Bilinsky | Chief Operating Officer | MIXED | +3,837 | −$34.59K |
| 2026-09-10 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +8,988 | −$57.75K |
| 2026-09-10 | Raj K. Puri | Chief Regulatory Officer | MIXED | +5,288 | −$38.96K |
| 2026-09-03 | Raj K. Puri | Chief Regulatory Officer | MIXED | +2,962 | −$20.77K |
| 2026-09-03 | Igor Bilinsky | Chief Operating Officer | MIXED | +4,317 | −$37.03K |
| 2026-09-03 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +23,967 | −$146.57K |
| 2026-08-12 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | +7,565 | −$15.59K |
| 2026-08-10 | Corleen M. Roche | Chief Financial Officer | MIXED | +28,757 | −$131.89K |
| 2026-06-18 | Raj K. Puri | Chief Regulatory Officer | A | +15,000 deriv. | — |
| 2026-06-18 | Ryan D Maynard | Director | A | +90,316 deriv. | — |
| 2026-06-18 | Athena Countouriotis | Director | A | +90,316 deriv. | — |
| 2026-06-18 | Iain D. Dukes | Director | A | +180,632 deriv. | — |
| 2026-06-18 | Michael Weiser | Director | A | +90,316 deriv. | — |
| 2026-06-09 | Finckenstein Friedrich Graf | Chief Medical Officer | MIXED | +3,837 | −$16.82K |
| 2026-06-09 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +8,987 | −$28.08K |
| 2026-06-09 | Raj K. Puri | Chief Regulatory Officer | MIXED | +5,923 | −$16.26K |
| 2026-06-09 | Igor Bilinsky | Chief Operating Officer | MIXED | +3,837 | −$16.82K |
| 2026-06-03 | Raj K. Puri | Chief Regulatory Officer | MIXED | +2,961 | −$9.93K |
| 2026-06-03 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +23,967 | −$70.10K |
| 2026-06-03 | Finckenstein Friedrich Graf | Chief Medical Officer | MIXED | +4,317 | −$17.71K |
| 2026-06-03 | Igor Bilinsky | Chief Operating Officer | MIXED | +4,317 | −$17.71K |
| 2026-05-13 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | +7,565 | −$9.01K |
| 2026-03-11 | Frederick G Vogt | Interim CEO & General Counsel | A | +235,000 deriv. | — |
| 2026-03-11 | Finckenstein Friedrich Graf | Chief Medical Officer | A | +58,750 deriv. | — |
| 2026-03-11 | Raj K. Puri | Chief Regulatory Officer | A | +117,500 deriv. | — |
| 2026-03-11 | Igor Bilinsky | Chief Operating Officer | A | +117,500 deriv. | — |
| 2026-03-11 | Daniel Gordon Kirby | Chief Commercial Officer | A | +132,200 deriv. | — |
| 2026-03-11 | Corleen M. Roche | Chief Financial Officer | A | +132,200 deriv. | — |
| 2026-03-06 | Finckenstein Friedrich Graf | Chief Medical Officer | MIXED | +14,726 | −$75.66K |
| 2026-03-06 | Igor Bilinsky | Chief Operating Officer | MIXED | +14,618 | −$76.16K |
| 2026-03-06 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +35,738 | −$122.54K |
| 2026-03-06 | Raj K. Puri | Chief Regulatory Officer | MIXED | +20,699 | −$84.09K |
| 2026-03-04 | Raj K. Puri | Chief Regulatory Officer | MIXED | +2,672 | −$10.60K |
| 2026-03-04 | Igor Bilinsky | Chief Operating Officer | MIXED | +5,404 | −$26.16K |
| 2026-03-04 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +29,278 | −$86.45K |
| 2026-03-04 | Finckenstein Friedrich Graf | Chief Medical Officer | MIXED | +5,575 | −$26.99K |
| 2026-02-26 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | +85,835 | −$129.14K |
| 2026-02-12 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | +23,546 | −$42.77K |
| 2025-12-03 | Raj K. Puri | Chief Regulatory Officer | MIXED | +3,002 | −$5.50K |
| 2025-12-03 | Igor Bilinsky | Chief Operating Officer | MIXED | +6,055 | −$13.78K |
| 2025-12-03 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +29,959 | −$48.94K |
| 2025-12-03 | Finckenstein Friedrich Graf | Chief Medical Officer | MIXED | +6,247 | −$14.20K |
| 2025-09-04 | Raj K. Puri | Chief Regulatory Officer | MIXED | +3,003 | −$5.40K |
| 2025-09-04 | Igor Bilinsky | Chief Operating Officer | MIXED | +6,056 | −$13.69K |
| 2025-09-04 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | +29,959 | −$48.46K |
| 2025-09-04 | Finckenstein Friedrich Graf | Chief Medical Officer | MIXED | +6,249 | −$14.12K |
| 2025-08-08 | Corleen M. Roche | Chief Financial Officer | A | +450,000 deriv. | — |
| 2025-06-17 | Wendy L Yarno | Director | A | +67,546 deriv. | — |
| 2025-06-17 | Michael Weiser | Director | A | +67,546 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Frederick G Vogt | Interim CEO & General Counsel | 602,085 | $8.56M |
| Raj K. Puri | Chief Regulatory Officer | 260,842 | $3.71M |
| Daniel Gordon Kirby | Chief Commercial Officer | 154,511 | $2.20M |
| Igor Bilinsky | Chief Operating Officer | 146,050 | $2.08M |
| Michael Weiser | Director | 141,116 | $2.01M |
| Finckenstein Friedrich Graf | Chief Medical Officer | 140,111 | $1.99M |
| Jean-Marc Bellemin | Chief Financial Officer | 64,993 | $923.55K |
| Iain D. Dukes | Director | 54,000 | $767.34K |
| Corleen M. Roche | Chief Financial Officer | 49,995 | $710.43K |
| Ryan D Maynard | Director | 7,500 | $106.58K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IOVA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.